Lung Cancer

The Food and Drug Administration expanded the approval for the first and only companion diagnostic to identify patients with non-small cell lung cancer who would benefit from Keytruda treatment.

Researchers found significant gender and role differences regarding cardiovascular disease incidence and its related health behaviors among cancer survivors and their spouses.

The Food and Drug Administration approved Keytruda (pembrolizumab) for the first-line treatment of patients with a lower PD-L1 cutoff in non-small cell lung cancer.

Survey results show that when one or more chronic condition was present physicians discussed trial participation with less than half of patients.

Previously treated patients with advanced small cell lung cancer (SCLC) benefitted from immunotherapy.

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

Patients with previously treated, advanced NSCLC who received Opdivo therapy experienced a survival benefit over many years, according to a pooled analysis of four studies.

Liquid biopsies may be less invasive and faster in determining the genetics of a tumor — and with high accuracy — among those diagnosed with non-small cell lung cancer.

Going through a cancer diagnosis and treatment is so difficult. Thanks to my care team suggesting proton therapy, I never felt like my life became consumed by my lung cancer diagnosis.